@article {6125,
	title = {{\ss}-synuclein aggregates and induces neurodegeneration in dopaminergic neurons.},
	journal = {Annals of Neurology},
	volume = {74},
	year = {2013},
	month = {2013 Mar 28},
	pages = {109-18},
	abstract = {<p>Objective: While the contribution of α-Synuclein to neurodegeneration in Parkinson{\textquoteright}s disease is well accepted, the putative impact of its close homologue, β-Synuclein, is enigmatic. β-Synuclein is widely expressed throughout the central nervous system as is α-Synuclein, but the physiological functions of both proteins remain unknown. Recent findings supported the view that β-Synuclein can act as an ameliorating regulator of α-Synuclein-induced neurotoxicity, having neuroprotective rather than neurodegenerative capabilities, and being non-aggregating due to absence of most part of the aggregation-promoting NAC domain. However, a mutation of β-Synuclein linked to dementia with Lewy bodies rendered the protein neurotoxic in transgenic mice and fibrillation of β-Synuclein has been demonstrated in vitro. Methods / Results: Supporting the hypothesis that β-Synuclein can act as a neurodegeneration-inducing factor we now demonstrate that wild-type β-Synuclein is neurotoxic for cultured primary neurons. Furthermore, β-Synuclein formed proteinase K resistant aggregates in dopaminergic neurons in vivo, leading to pronounced and progressive neurodegeneration in rats. Expression of β-Synuclein caused mitochondrial fragmentation, but this fragmentation did not render mitochondria non-functional in terms of ion handling and respiration even in late stages of neurodegeneration. A comparison of the neurodegenerative effects induced by α-, β-, and γ-Synuclein revealed that β-Synuclein was eventually as neurotoxic as α-Synuclein for nigral dopaminergic neurons, while γ-Synuclein proved to be non-toxic and had very low aggregation propensity. Interpretation: Our results suggest that the role of β-Synuclein as a putative modulator of neuropathology in aggregopathies like Parkinson{\textquoteright}s disease and dementia with Lewy bodies needs to be revisited. ANN NEUROL 2013. {\textcopyright} 2013 American Neurological Association.</p>
},
	issn = {1531-8249},
	doi = {10.1002/ana.23905},
	author = {Taschenberger, G and Toloe, J and Tereshchenko, J and Akerboom, J and Wales, P and Benz, R and Becker, S and Outeiro, Tf and Looger, L and B{\"a}hr, M and Zweckstetter, M and K{\"u}gler, S}
}
